Daewon Pharmaceutical Reports H1 Operating Profit of 4.4 Billion Won, Down 45.3% Due to Increased R&D and Marketing Expenses
Daewon Pharmaceutical announced on August 7 that its consolidated operating profit for the first half of this year was 4.4 billion won, a decrease of 45.3% compared to the same period last year. During the same period, sales increased by 3.1% to 310.9 billion won, and net profit for the period was reported at 5.7 billion won.
The company explained that profitability declined due to an increase in selling and administrative expenses, which was caused by research and development (R&D) costs for new drug development, as well as higher marketing expenses for the launch of new health functional foods.
Hot Picks Today
"I Went for the Cheap Coffee, but Now I Feel Uneasy"... Major Coffee Franchises Cited for Violations One After Another
- In Korea, Studying Medicine Is in High Demand, but in China, It's Shunned: "Why Become a Doctor When You Can’t Make Money?"
- "Surprisingly Real, Perfect Like AI" -- Global Media Praise Korean Fencer's Beauty
- "50 Million Won for Weekly Encounters"... Man in His 60s Sentenced for Deceiving Woman in Her 20s with Forged 1.4 Billion Won Account
- "I've Already Booked My Trip to Japan, But This Is Serious"...Highest Number of Measles Cases in Japan in a Decade Spurs Emergency Alert
On the other hand, sales in the first half continued to grow, driven by increased prescriptions for products treating chronic diseases and strong sales of health functional foods.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
